Clinical Research Directory

Inclusion Criteria:Age: Patients must be 18 years of age or older. * Diagnosis:Patients diagnosed with non-metastatic cervical cancer stages IB2 to IVA, as per the FIGO staging system. * Treatment Plan: Patients scheduled to undergo definitive chemo-radiotherapy or adjuvant chemo-radiotherapy post-surgery. * Bone Health: No history of osteoporosis or previous treatment with bisphosphonates or other bone-modifying agents. * Pain Assessment: Patients experiencing bone pain or at risk of developing pelvic insufficiency fractures, despite current standard of care. * Recent Imaging: Patients must have undergone recent imaging (CT, PET, or MRI) within the last 3 months to confirm the absence of bone metastases. * Compliance: Patients must be able to comply with the study protocol and follow-up schedule. Psychological, familial, sociological, or geographical conditions that could hamper compliance need to be evaluated and discussed before trial registration. * Consent: Patients must provide written informed consent before participating in the study Exclusion Criteria:Age: Patients under 18 years of age. * Performance Status: Patients with an ECOG Performance Status of 2, 3 or 4. * Bone Metastases: Presence of bone metastases. * Contraindications to Alendronate: Known contraindications to alendronate, such as esophageal disorders, inability to sit or stand upright for at least 30 minutes, severe renal impairment (creatinine clearance \<35 mL/min), or hypersensitivity to any component of the product. * Concurrent Treatments: Patients receiving other concurrent treatment with bisphosphonates, denosumab, or other bone-modifying agents. * Special Populations: Pregnant or breastfeeding women, prisoners, and patients with major psychiatric illnesses that could interfere with adherence to study requirements. * Previous Treatment: Patients who have previously received radiotherapy to the pelvic region.